



azaCITIDine 75mg/m² 5-2-2 Therapyⁱ

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen	Reimbursement
INDICATION	ICD10	Code	Status
Intermediate-1 and low risk myelodysplastic syndromes	D46	00287a	Hospital
(MDS) according to the International Prognostic Scoring			
System (IPSS) ⁱⁱ			
Treatment of adult patients who are not eligible for haematop	oietic stem cell	transplanta	tion with:
Intermediate-2 and high risk myelodysplastic syndromes	D46	00287b	Hospital
(MDS) according to the International Prognostic Scoring			
System (IPSS)			
Chronic myelomonocytic leukaemia (CMML) with 10-29%	C93	00287c	Hospital
marrow blasts without myeloproliferative disorder			
Acute myeloid leukaemia (AML) with 20-30% blasts and multi-	C92	00287d	Hospital
lineage dysplasia, according to WHO classification			

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

azaCITIDine is administered daily for 5 days (Mon-Fri), followed by a rest period of 2 days and then treated again on Day 8 & 9 (Monday and Tuesday) followed by a rest period of 19 days (28-day treatment cycle) for a **minimum** of 6 cycles or until unacceptable toxicity or disease progression occurs.

Day	Drug	Dose	Route and Method of Administration
1-5	azaCITIDine	75mg/m ²	*SC using a 25-gauge needle into upper arm, thigh or abdomen
8-9	azaCITIDine	75mg/m ²	*SC using a 25-gauge needle into upper arm, thigh or abdomen

^{*}Doses > 4ml should be equally divided into 2 syringes and injected into two separate sites.

Injection sites should be rotated. New injections should be given at least 2.5 cm from the previous site and never into areas where the site is tender, bruised, red, or hardened.

Note: In individual cases where approved by Consultant azaCITIDine may be administered as IV Infusion in 100ml NaCl 0.9% over 10 minutes. Note that this is an unlicensed method of administration.

ELIGIBILITY:

Indications as above

NCCP Regimen: azaCITIDine 75mg/m² 5-2-2 Therapy	Published: 17/10/2018 Review: 01/03/2026	Version number: 2c
Tumour Group: Leukaemia NCCP Regimen Code: 00287	IHS Contributor: Dr Kamal Fadalla	Page 1 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer





EXCLUSIONS:

- Hypersensitivity to azaCITIDine, or to any of the excipients.
- Advanced malignant hepatic tumours.
- Breastfeeding.

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Haematologist working in the area of haematological malignancies

TESTS:

Baseline tests:

- FBC, renal and liver profile
- Coagulation screen
- Virology screen Hepatitis B (HBsAg, HBcoreAb), Hepatitis C, HIV.
 *Hepatitis B reactivation: See Adverse effects/ Regimen specific complications

Regular tests:

- FBC at a minimum prior to each treatment cycle or more frequently as clinically indicated depending on level of cytopenia or haematological toxicity experienced.
- Renal and liver profile prior to each cycle

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

• Any dose modification should be discussed with a Consultant

Haematological:

- No dose modification with first cycle. Commence azaCITIDine at 100% dose in the first cycle regardless of baseline haematology counts. Platelet transfusions may be needed.
- Haematological toxicity is defined as the lowest count reached in a given cycle (nadir) if platelets $\leq 50 \times 10^9/L$ and/or absolute neutrophil count (ANC) $\leq 1 \times 10^9/L$.
- Recovery is defined as blood count at recovery ≥ nadir count + (0.5 x [baseline count nadir count]).

For patients without reduced baseline counts (i.e. WBC \geq 3 x 10 9 /L, ANC \geq 1.5 x 10 9 /L, and platelets \geq 75 x 10 9 /L prior to Cycle 1) see Table 1 for dose modifications.

NCCP Regimen: azaCITIDine 75mg/m ² 5-2-2 Therapy	Published: 17/10/2018 Review: 01/03/2026	Version number: 2c
Tumour Group: Leukaemia NCCP Regimen Code: 00287	IHS Contributor: Dr Kamal Fadalla	Page 2 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer





Table 1: Dose modification of azaCITIDine based on nadir neutrophil and platelet count in patients without reduced baseline counts

Nadir Neutrophils (x 10 ⁹ /L)		Nadir Platelets (x 10 ⁹ /L)	azaCITIDine dose
>1	and	>50	100% dose
≤1	or	≤50	Delay treatment until cell counts recover. If recovery < 14 days beyond scheduled start date (i.e. < 6 weeks from previous course) treat with 100% dose
≤ 1	or	≤50	If recovery > 14 days beyond scheduled start date (i.e. > 6 weeks from previous course) treat with 50% of previous cycle dose


NCCP Regimen: azaCITIDine 75mg/m ² 5-2-2 Therapy	Published: 17/10/2018 Review: 01/03/2026	Version number: 2c
Tumour Group: Leukaemia NCCP Regimen Code: 00287	IHS Contributor: Dr Kamal Fadalla	Page 3 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer





For patients with reduced baseline counts (i.e. WBC < 3×10^9 /L or ANC < 1.5×10^9 /L or platelets < 75×10^9 /L) prior Cycle 1) dose modification are outlined in Figure 1 below:



* blood count at recovery ≥ nadir count + (0.5 x [baseline count – nadir count])

Figure 1: Dose modification of azaCITIDine based on nadir neutrophil and platelet count in patients with reduced baseline counts

NCCP Regimen: azaCITIDine 75mg/m² 5-2-2 Therapy	Published: 17/10/2018 Review: 01/03/2026	Version number: 2c
Tumour Group: Leukaemia NCCP Regimen Code: 00287	IHS Contributor: Dr Kamal Fadalla	Page 4 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer





Renal and Hepatic Impairment:

Table 2: Dose modification of azaCITIDine in renal and hepatic impairment

Renal Impairment		Hepatic Impairment	
No initial dose adjustment with renal impairment Dose adjustment recomm bicarbonate, creatinine an	ended for serum	No specific modification to the starting dose is recommended for patients with hepatic impairment prior to starting treatment. Subsequent dose modifications should be based	
Unexplained reductions in serum bicarbonate level to < 20mmol/L	Reduce dose by 50%	on haematology laboratory values. Patients with severe hepatic organ impairment should be carefully monitored for adverse events. azaCITIDine is contraindicated in patients with	
Unexplained elevation in serum creatinine or BUN to ≥ 2 above baseline and ULN	Delay next cycle until values return to normal or baseline and reduce the dose by 50% on next treatment cycle	advanced malignant hepatic tumours.	

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

 As outlined in NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting linked <u>here</u>

azaCITIDine: Moderate (Refer to local policy)

For information:

Within NCIS regimens, antiemetics have been standardised by Medical Oncologists and Haemato-oncologists and information is available in the following documents:

- NCCP Supportive Care Antiemetic Medicines for Inclusion in NCIS (Medical Oncology) link <u>here</u>
- NCCP Supportive Care Antiemetic Medicines for Inclusion in NCIS (Haemato-oncology) link here

PREMEDICATIONS: Not usually required

OTHER SUPPORTIVE CARE:

- Tumour Lysis Syndrome prophylaxis (Refer to local policy).
- Antifungal prophylaxis (if tolerated), for patients with baseline cytopenia or persistent neutropenia, continued until haematological improvement (Refer to local policy).
- Both diarrhoea and constipation are common side effects associated with azaCITIDine treatment. Patients may require either laxatives or anti-diarrhoeals.
- Women of childbearing potential and men must use effective contraception during and up to 3 months after treatment.
- Consider topical hydrocortisone 1% for treatment of local allergic skin reactions.

NCCP Regimen: azaCITIDine 75mg/m ² 5-2-2 Therapy	Published: 17/10/2018 Review: 01/03/2026	Version number: 2c
Tumour Group: Leukaemia NCCP Regimen Code: 00287	IHS Contributor: Dr Kamal Fadalla	Page 5 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer





ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- Haematological toxicity: Fever or other evidence of infection must be assessed promptly and treated appropriately. Treatment with azaCITIDine is associated with anaemia, neutropenia and thrombocytopenia, particularly during the first 2 cycles. Patients and physicians are also advised to be observant for signs and symptoms of bleeding.
- Hepatic impairment: Patients with extensive tumour burden due to metastatic disease have been reported to experience progressive hepatic coma and death during azaCITIDine treatment; especially in such patients with baseline serum albumin< 30 g/L. azaCITIDine is contraindicated in patients with advanced malignant hepatic tumours.
- Renal impairment: Patients should be advised to report any oliguria and anuria to the health
 care provider immediately. Patients with renal impairment should be closely monitored for
 toxicity since azaCITIDine and/or its metabolites are primarily excreted by the kidney.
- Cardiac and pulmonary disease: Recent data from a clinical trial in patients with a known history
 of cardiovascular or pulmonary disease showed a significantly increased incidence of cardiac
 events with azaCITIDine. It is therefore advised to exercise caution when prescribing azaCITIDine
 to these patients. Cardiopulmonary assessment before and during the treatment should be
 considered.
- Necrotising fasciitis: Necrotising fasciitis, including fatal cases, have been reported in patients
 treated with azaCITIDine. Therapy with azaCITIDine should be discontinued in patients who
 develop necrotising fasciitis, and appropriate treatment should be promptly initiated.
- Hepatitis B Reactivation: Patients should be tested for both HBsAg and HBcoreAb as per local
 policy. If either test is positive, such patients should be treated with anti-viral therapy (Refer to
 local infectious disease policy). These patients should be considered for assessment by
 hepatology.

DRUG INTERACTIONS:

- Clinically significant inhibitory or inductive effects of azaCITIDine on cytochrome P450 enzymes are unlikely.
- No formal clinical drug interaction studies with azaCITIDine have been conducted.

REFERENCES:

- 1. Silverman, LR et al., Randomized controlled trial of azaCITDine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol, 2002; 20(10):2429-40.
- 2. Fenaux P et al. Efficacy of azaCITIDine compared with conventional care regimens in the treatment of higher-risk Myelodysplastic syndromes: a randomised open label, phase III study. Lancet Oncol. 2009;10:223-32
- 3. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azaCITIDine in patients with myelodysplastic syndromes. J Clin Onc 2009; 27(11):1850-6.

NCCP Regimen: azaCITIDine 75mg/m² 5-2-2 Therapy	Published: 17/10/2018 Review: 01/03/2026	Version number: 2c
Tumour Group: Leukaemia NCCP Regimen Code: 00287	IHS Contributor: Dr Kamal Fadalla	Page 6 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer





- 4. Garcia-Delgado, R et al. Effectiveness and safety of different azaCITIDine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leuk Res 2014; 38 (7); 744-750
- Fenaux P et al. azaCITIDine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia. J Clin Onc 2010;28(4):562-569
- 6. azaCITIDine (VIDAZA®) Summary of Product Characteristics. Accessed Feb 2021. Available at: https://www.ema.europa.eu/en/documents/product-information/vidaza-epar-product-information en.pdf
- NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V5 2023. Available at: https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-

document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf

Version	Date	Amendment	Approved By
1	17/10/2018		Dr Kamal Fadalla
2	01/03/2021	Updated Adverse effects (Hepatitis B reactivation)	Dr Kamal Fadalla
2c	05/07/2024	Updated information in the Emetogenic Potential section.	NCCP

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

NCCP Regimen: azaCITIDine 75mg/m² 5-2-2 Therapy	Published: 17/10/2018 Review: 01/03/2026	Version number: 2c
Tumour Group: Leukaemia NCCP Regimen Code: 00287	IHS Contributor: Dr Kamal Fadalla	Page 7 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer

ⁱ This dosing regimen is outside its licensed indication in Ireland. Patients should be informed of the unlicensed nature of this regimen and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or "off label" indications. Prescribers should be aware of their responsibility in communicating any relevant information to the patient and also in ensuring that the unlicensed or "off label" indication has been acknowledged by the hospital's Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.

ii This indication is outside the licensed indications for azaCITIDine in Ireland. Patients should be informed of the unlicensed nature of this regimen and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or "off label" indications. Prescribers should be aware of their responsibility in communicating any relevant information to the patient and also in ensuring that the unlicensed or "off label" indication has been acknowledged by the hospital's Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.